PDGFR alpha [p Tyr762] Antibody [Unconjugated]

Western blot shows lysates of human foreskin fibroblast untreated (-) or treated (+) with 100 ng/mL Recombinant Human PDGF-AA (Catalog # 221-AA) or Recombinant Human PDGF-BB (Catalog # 220-BB) for 10 minutes. PVDF membrane was probed with 0.5 µg/mL of Human Phospho-PDGF Ra (Y762) Antigen Affinity-purified Polyclonal Antibody (Catalog # AF21141), followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for Phospho-PDGF Ra (Y762) at approximately 180 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

c-MET and PDGFR alpha signals are crucial for the proliferation of SS cells. a Phosphorylation status of RTKs in 3 SS cell lines. b Yamato-SS (3 × 103), SYO-1 (5 × 103) and HS-SY-II (1 × 104) cells were transfected with siRNAs against c-MET. Transfected cells were cultured for 96 h and relative cell proliferation rates were measured using a WST-1 assay. Bars represent the SD. * p < 0.05. c Growth of Yamato-SS (3 × 103), SYO-1 (5 × 103) and HS-SY-II (1 × 104) cells transfected with siRNAs against PDGFR alpha . Relative cell proliferation rates were determined using a WST-1 assay after 96 h. Bars represent the SD. * p < 0.05 Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28511645), licensed under a CC-BY license. Not internally tested by R&D Systems.

TAS-115 suppresses phosphorylation of c-MET and PDGFR alpha , as well as their downstream effectors. a Yamato-SS cells (c-MET-dependent SS cells) were treated with 0.001–10 μM of TAS-115 or control (0.1% DMSO) for 3 h. b SYO-1 and HS-SY-II cells (PDGFR alpha -dependent SS cells) were treated with 0.001–10 μM of TAS-115 or control (0.1% DMSO) for 3 h Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28511645), licensed under a CC-BY license. Not internally tested by R&D Systems.

Inhibitory activities of TAS-115 and pazopanib on c-MET, PDGFR alpha and their downstream effectors in vitro. a Yamato-SS cells (c-MET-dependent SS cells) were treated with 0.1 μM TAS-115 or pazopanib or control (0.1% DMSO) for 3 h. b Yamato-SS cells were treated with 0.001–20 μM of pazopanib or control (0.1% DMSO) for 3 h. c SYO-1 and HS-SY-II (PDGFR alpha -dependent) SS cells were treated with 10-μM TAS-115 or pazopanib or control (0.1% DMSO) for 3 h, followed by an additional treatment with rhPDGF-BB at a concentration of 10 ng/ml for the last 15 min Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28511645), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, IHC
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: LYOPH

PDGFR alpha [p Tyr762] Antibody [Unconjugated] Summary

• Immunogen: Phosphopeptide containing human PDGF R alpha Y762 site
• Modification: p Tyr762
• Specificity: Detects human PDGF R alpha when phosphorylated at Y762.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: PDGFRA
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Western Blot 0.5 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PDGFR alpha [p Tyr762] Antibody [Unconjugated]

• alpha-type platelet-derived growth factor receptor
• CD140 antigen-like family member A
• CD140a antigen
• CD140a
• EC 2.7.10
• EC 2.7.10.1
• MGC74795
• PDGF R alpha
• PDGFR alpha
• PDGFR2
• PDGFRA
• PDGFRA/BCR fusion
• PDGF-R-alpha
• platelet-derived growth factor receptor, alpha polypeptide
• rearranged-in-hypereosinophilia-platelet derived growth factor receptor alphafusion protein
• RHEPDGFRA

Background

PDGF is a major serum mitogen that can exist as a homo- or heterodimeric protein consisting of disulfide-linked PDGF-A and PDGF-B chains. The PDGF-AA, PDGF‑BB and PDGF-AB isoforms have been shown to bind to two distinct cell surface PDGF receptors with different affinities. Whereas PDGF R alpha binds all three PDGF isoforms with high affinity, PDGF R beta binds PDGF-BB and AB, but not PDGF-AA. Both PDGF R alpha and PDGF R beta are members of the class III subfamily of receptor tyrosine kinases (RTK) that also includes the receptors for M-CSF, SCF and Flt3 ligand. All class III RTKs are characterized by the presence of five immunoglobulin-like domains in their extracellular region and a split kinase domain in their intracellular region. PDGF binding induces receptor homo- and heterodimerization and signal transduction. The expression of the alpha and beta receptors is independently regulated in various cell types. Only PDGF R alpha is expressed in oligodendrocyte progenitor cells, mesothelial cell and liver endothelial cells. Soluble PDGF-R alpha has been detected in cell conditioned medium and human plasma. Recombinant soluble PDGF R alpha binds PDGF with high affinity and is a potent PDGF antagonist (1).

1. Heldin, C.H. and L. Claesson-Welsh (1994) Guidebook to Cytokines and Their Receptors, Nicola, N.A. (ed) Oxford University Press, New York, NY p. 202.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for PDGFR alpha Antibody (AF21141)(1)

Publication using AF21141

• S Yamada, Y Imura, T Nakai, S Nakai, N Yasuda, K Kaneko, H Outani, S Takenaka, K Hamada, A Myoui, N Araki, T Ueda, K Itoh, H Yoshikawa, N Naka Therapeutic potential of TAS-115 via c-MET and PDGFR? signal inhibition for synovial sarcoma BMC Cancer, 2017-05-16;17(1):334. 2017-05-16 [PMID: 28511645] (Western Blot, Human)

Bioinformatics

• Gene Symbol: PDGFRA